Targeting the tumor-draining lymph node with adjuvant nanoparticles for cancer immunotherapy

摘要

Together, this work implicates the TDLN as a novel drug delivery target for immunotherapy of solid tumors. Moreover, these data indicate that biomaterials engineering strategies can enhance the potential of Adjs in the effective activation of immune reactions against tumors for cancer immunotherapy applications.